# US 8,278,343 B2 · Pyrrolidines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,343 B2
- Document ID: US8278343B2
- Status: Granted
- Kind: B2
- Application number: 12/613,771
- Filed: 2009-11-06
- Published: 2010-05-13
- Granted: 2012-10-02
- Earliest claimed: 2008-11-10
- Assignees: Pfizer Inc.
- Inventors: Kevin N. Dack; James E. Mills; Sarah E. Skerratt
- Web page: https://patentgrep.com/patent/US8278343B2

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 5/24: of the sex hormones
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutically acceptable derivatives thereof, to their use in medicine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds of formula (I) are useful for the treatment of EP2-mediated conditions, such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome.

## Claims

### Claim 1

A compound of formula (I):
wherein:
R1 is a phenyl group optionally substituted by one or two substituents independently selected from F, Cl, Br, CN, C1-4 alkyl, C1-4 alkylthio and C1-4 alkoxy, fluoro-C1-6 alkyl and fluoro-C1-6 alkoxy, or a C3-6 cycloalkyl group;
X represents a direct link, NH, or O;
Z is selected from
R2 is H or C1-6 alkyl (optionally substituted with 1 to 3 fluorine atoms);
R3 is C1-6 alkyl (optionally substituted with 1 to 3 fluorine atoms);
Ar is an aromatic group consisting of 1, 2 or 3 aromatic rings, which aromatic rings are independently selected from phenyl and a 5- or 6-membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and which aromatic rings, if there are 2 or more, can be fused or linked by one or more covalent bond, and which aromatic rings are optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, CN, OH, C1-6 alkyl, C1-6 alkylthio, fluoro-C1-6 alkyl, fluoro-C1-6 alkylthio, fluoro-C1-6 alkoxy, C1-6 alkoxy, SO2R4, NR5R6, NHSO2R7, SO2NR8R9, and NHCOR12;
R4 and R7 are each independently C1-6 alkyl (optionally substituted by 1 to 3 fluorine atoms);
R5, R6, R8, R9, R10, R11 and R12 are each independently H or C1-6 alkyl (optionally substituted by 1 to 3 fluorine atoms);
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein R1 is a phenyl group optionally substituted by one or two substituents independently selected from F, Cl and C1-4 alkoxy, or a C3-6 cycloalkyl group, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein X represents a direct link, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound according to claim 1 wherein Z is
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein R2 is H, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein Ar is a biphenyl, pyridinylphenyl, pyrimidinylphenyl or pyrazinylphenyl group, optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, CN, OH, C1-6 alkyl, C1-6 alkylthio, fluoro-C1-6 alkyl, fluoro-C1-6 alkylthio, fluoro-C1-6 alkoxy, C1-6 alkoxy, SO2R4, NR5R6, NHSO2R7, SO2NR8R9, CONR10R11 and NHCOR12, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

A compound according to claim 6, wherein Ar is a biphenyl, pyridinylphenyl, pyrimidinylphenyl or pyrazinylphenyl optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, CN, and a C1-6 alkoxy group, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A compound according to claim 1, which is a compound of formula (Ia)
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A compound according to claim 1, which is a compound of formula (Ib)
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or adjuvant.

### Claim 11 (depends on 1)

A method of treating endometriosis, uterine fibroids, menorrhagia, adenomyosis, primary dysmenorrhoea and secondary dysmenorrhoea or, chronic pelvic pain syndrome, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the compound is administered as a pharmaceutical composition comprising a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, and a and a pharmaceutically acceptable diluent, carrier or adjuvant.
